Recap: Bakkt Hldgs Q3 Earnings

Bakkt Hldgs (NYSE:BKKT) reported its Q3 earnings results on Tuesday, November 14, 2023 at 07:30 AM. Here’s what…

Bakkt Hldgs (NYSE:BKKT) reported its Q3 earnings results on Tuesday, November 14, 2023 at 07:30 AM.

Here’s what investors need to know about the announcement.

Earnings

Bakkt Hldgs missed estimated earnings by 11.76%, reporting an EPS of $-0.19 versus an estimate of $-0.17.

Revenue was up $191.90 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.01 which was followed by a 3.65% increase in the share price the next day.

Here’s a look at Bakkt Hldgs’s past performance:

Quarter Q2 2023 Q1 2023 Q4 2022 Q3 2022
EPS Estimate -0.20 -0.18 -0.18 -0.12
EPS Actual -0.19 -0.17 -1.24 -6.11
Revenue Estimate 17.20M 14.35M 15.88M 14.10M
Revenue Actual 347.60M 13.00M 15.60M 12.90M

To track all earnings releases for Bakkt Hldgs visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug

Substance use disorder-focused biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) reported on Tuesday second quarter financial results for the three months ended Dec. 31, 2023, The company's primary focus is on developing therapy for acute cannabinoid intoxication (ACI).Total operating expenses in the second quarter of fiscal 2024 were $2.8 million compared with $3.8 million in the same period in fiscal 2023.Net loss in the second quarter of fiscal 2024 was $2.7 million, or $(0.11) per share, compared with a net loss of $3.8 million, or $(0.15) per share, in the second quarter of fiscal 2023.

ANEB